was erwartet uns noch bei biolife solutions (WKN: 894679)? bisher haben die noch keine aktienverwässerung am otcbb durchgeführt,hoffentlich bleibt das so, denn dann könnte das langfristig noch ne perle werden...der wert hatte zeitweise auffälliges volumen und dann wieder so gut wie null handel...halt nur was für spekulanten! ich könnte mir sogar ein wechsel des börsensegments vorstellen...siehe news der vergangenheit...www.otcbb.com
August 15, 2005 - 7:30 AM EDT
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
BLFS 0.07 -0.01
Today 5d 1m 3m 1y 5y 10y
BioLife Solutions Granted U.S. Patent Covering New Method of Preserving Cells, Tissues or Organs
OWEGO, N.Y., Aug. 15 /PRNewswire-FirstCall/ -- BioLife Solutions Inc. (OTC Bulletin Board: BLFS) announced today that it was granted a U.S. patent that covers the methods and compositions for the preservation of cells, tissues or organs in the vitreous state.
BioLife President and CEO John G. Baust, Ph.D., said that the market for preserving cells and tissue is growing rapidly and is diverging into new technology areas, one of which is vitrification or freezing rapidly to avoid the presence of ice crystals.
Baust said, 'Our core preservation technologies can be a critical factor in applying this new technology and solidifying our patent position in that area gives us a commercial foothold as that market develops.' He continued, 'We believe BioLife holds a unique and encompassing intellectual property position in the biological processing and preservation of cells, tissues and organs and that our technology significantly improves the viability of cells and organs for longer periods of time during transportation and storage.'
The issuance of the patent specifically provides BioLife with the latest extension of its molecular-based cryopreservation technology platform and protects BioLife's use of cell death inhibitors (calpain inhibitors) in hypothermic preservation solutions necessary to improve cryopreservation outcome. With this patent the scope of the Company's proprietary preservation technology extends into the cell, tissue and organ vitrification arena by including the Company's molecular-based approaches to preservation to prevent apoptotic and necrotic cell death following the preservation process.
This patent, No. 6,921,633, titled, 'Methods and compositions for the preservation of cells, tissues or organs in the vitreous state,' brings the total number of issued patents that relate to its preservation solutions to four.
About BioLife Solutions, Inc.
BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on the Company's proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. The expanding practice of cell and gene therapy has created a need for products that ensure the biological viability of mammalian cell and tissue material during transportation and storage. The HypoThermosol(R) and CryoStor(TM) products that the Company is selling today are a significant step forward in meeting these needs.
This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Contact: Allen & Caron Inc
Jill Bertotti (investors)
jill@allencaron.com
Len Hall (media)
len@allencaron.com
949-474-4300
SOURCE BioLife Solutions Inc.
Source: PR Newswire (August 15, 2005 - 7:30 AM EDT)
News by QuoteMedia
www.quotemedia.com
BIOLIFE SOLUTIONS INC: NT 10-K, Sub-Doc 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
Commission File Number 0-18170
NOTIFICATION OF LATE FILING
(Check One): [X] Form 10-K and Form 10-KSB [ ] Form 11-K [ ] Form 20-F [ ]
Form 10-Q and Form 10-QSB [ ] Form N-SAR
For Period Ended: December 31, 2005
--------------------------------------------------
[ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q
[ ] Transition Report on Form 20-F [ ] Transition Report on Form N-SAR
[ ] Transition Report on Form 11-K
For Transition Period Ended:__________________________________________________
Read attached instruction sheet before preparing form. Please print or type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
BioLife Solutions, Inc.
--------------------------------------------------
Full name of registrant
--------------------------------------------------
Former name if applicable
171 Front Street
--------------------------------------------------
Address of principal executive office (Street and number)
Owego, NY 13827
--------------------------------------------------
City, State and Zip Code
PART II - RULES 12B-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check appropriate box.)
(a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, transition report on Form
10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or
before the fifteenth calendar day following the prescribed due date; or the
subject quarterly report or transition report on Form 10-Q, or portion
thereof will be filed on or before the fifth calendar day following the
prescribed due date; and
(c) The account's statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K,
10-Q, N-SAR or the transition report portion thereof could not be filed within
the prescribed time period. (Attach extra sheets if needed.)
The registrant's annual report on Form 10-KSB is being filed
late because subsequent to the year ended December 31, 2005, the
Company engaged in financing activities seeking to raise additional
funds that the Company will file on Form 10KSB as a subsequent event.
WKN: 894679
August 15, 2005 - 7:30 AM EDT
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
BLFS 0.07 -0.01
Today 5d 1m 3m 1y 5y 10y
BioLife Solutions Granted U.S. Patent Covering New Method of Preserving Cells, Tissues or Organs
OWEGO, N.Y., Aug. 15 /PRNewswire-FirstCall/ -- BioLife Solutions Inc. (OTC Bulletin Board: BLFS) announced today that it was granted a U.S. patent that covers the methods and compositions for the preservation of cells, tissues or organs in the vitreous state.
BioLife President and CEO John G. Baust, Ph.D., said that the market for preserving cells and tissue is growing rapidly and is diverging into new technology areas, one of which is vitrification or freezing rapidly to avoid the presence of ice crystals.
Baust said, 'Our core preservation technologies can be a critical factor in applying this new technology and solidifying our patent position in that area gives us a commercial foothold as that market develops.' He continued, 'We believe BioLife holds a unique and encompassing intellectual property position in the biological processing and preservation of cells, tissues and organs and that our technology significantly improves the viability of cells and organs for longer periods of time during transportation and storage.'
The issuance of the patent specifically provides BioLife with the latest extension of its molecular-based cryopreservation technology platform and protects BioLife's use of cell death inhibitors (calpain inhibitors) in hypothermic preservation solutions necessary to improve cryopreservation outcome. With this patent the scope of the Company's proprietary preservation technology extends into the cell, tissue and organ vitrification arena by including the Company's molecular-based approaches to preservation to prevent apoptotic and necrotic cell death following the preservation process.
This patent, No. 6,921,633, titled, 'Methods and compositions for the preservation of cells, tissues or organs in the vitreous state,' brings the total number of issued patents that relate to its preservation solutions to four.
About BioLife Solutions, Inc.
BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on the Company's proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. The expanding practice of cell and gene therapy has created a need for products that ensure the biological viability of mammalian cell and tissue material during transportation and storage. The HypoThermosol(R) and CryoStor(TM) products that the Company is selling today are a significant step forward in meeting these needs.
This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Contact: Allen & Caron Inc
Jill Bertotti (investors)
jill@allencaron.com
Len Hall (media)
len@allencaron.com
949-474-4300
SOURCE BioLife Solutions Inc.
Source: PR Newswire (August 15, 2005 - 7:30 AM EDT)
News by QuoteMedia
www.quotemedia.com
BIOLIFE SOLUTIONS INC: NT 10-K, Sub-Doc 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
Commission File Number 0-18170
NOTIFICATION OF LATE FILING
(Check One): [X] Form 10-K and Form 10-KSB [ ] Form 11-K [ ] Form 20-F [ ]
Form 10-Q and Form 10-QSB [ ] Form N-SAR
For Period Ended: December 31, 2005
--------------------------------------------------
[ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q
[ ] Transition Report on Form 20-F [ ] Transition Report on Form N-SAR
[ ] Transition Report on Form 11-K
For Transition Period Ended:__________________________________________________
Read attached instruction sheet before preparing form. Please print or type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
BioLife Solutions, Inc.
--------------------------------------------------
Full name of registrant
--------------------------------------------------
Former name if applicable
171 Front Street
--------------------------------------------------
Address of principal executive office (Street and number)
Owego, NY 13827
--------------------------------------------------
City, State and Zip Code
PART II - RULES 12B-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check appropriate box.)
(a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, transition report on Form
10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or
before the fifteenth calendar day following the prescribed due date; or the
subject quarterly report or transition report on Form 10-Q, or portion
thereof will be filed on or before the fifth calendar day following the
prescribed due date; and
(c) The account's statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K,
10-Q, N-SAR or the transition report portion thereof could not be filed within
the prescribed time period. (Attach extra sheets if needed.)
The registrant's annual report on Form 10-KSB is being filed
late because subsequent to the year ended December 31, 2005, the
Company engaged in financing activities seeking to raise additional
funds that the Company will file on Form 10KSB as a subsequent event.
WKN: 894679
